One of the biggest challenges the medical community faces in fighting cancer is the phenomenon of treatment resistance, which results in poor prognosis for patients due to the inability of available treatments to deliver meaningful beneficial changes in cancer progression. Understanding why this resistance exists is crucial for developing more effective therapies.
Scientists are currently preoccupied with finding ways to overcome acquired resistance to treatment in various cancer types and subtypes. Research has focused on several mechanisms, including genetic mutations, tumor heterogeneity, and the tumor microenvironment, which can all contribute to resistance. For instance, genetic alterations in cancer cells can render drugs ineffective, while the microenvironment can shield tumors from immune attack.
The team at Calidi Biotherapeutics Inc. (NYSE American: CLDI) is working to develop oncolytic virus therapies designed to equip the immune system with a powerful tool to fight cancer. These therapies use viruses that selectively infect and kill cancer cells while stimulating an immune response. This approach aims to overcome resistance by targeting tumors through multiple mechanisms.
Other strategies being explored include combination therapies that attack cancer from different angles, such as pairing immunotherapy with targeted drugs, and developing biomarkers to predict resistance. The goal is to personalize treatment based on a tumor's specific resistance profile.
The implications of this research are profound. If scientists can decipher the mechanisms of resistance and develop strategies to counteract them, it could dramatically improve outcomes for cancer patients. For now, treatment resistance remains a formidable barrier, but ongoing studies offer hope for new solutions.
